Company intelligence / Profile preview
Mallinckrodt Pharmaceuticals
- Ownership
- Public · MNKTQ
- Development stage
- Commercial
Overview
Mallinckrodt is a multibillion-dollar specialty pharmaceutical company with a portfolio of products for autoimmune and rare diseases, immunotherapy, neonatal respiratory care, analgesics and gastrointestinal products
- Therapeutic areas
- GastroenterologyPulmonologyPsychiatryNephrologyRheumatologyOphthalmologyImmunologyNeurology
- Modalities
- Small moleculescontrast media
- Industry
- Biotech
Drug pipeline
44 assets43 more assets in the full pipeline.
Request access →Financials
- Market cap
- $1.4B
- Total revenue
- $285.5M
- Enterprise value
- $1.8B
Beyond the preview
Go deeper on Mallinckrodt Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mallinckrodt Pharmaceuticals.